D21-2393 is known as Edoxaban 4-Carboxylic Acid. Subjects received a single-orally bioavailable-dose of edoxaban 30-90 mg in each study occasion under fasting condition. Serial blood samples were collected to measure the plasma concentrations of edoxaban and its major active metabolite D21-2393. Meanwhile, PT, INR, aPTT were measured pre- and post-dose. Safety was assessed. 4. The effects of edoxaban on all pharmacodynamic biomarkers were concentration-dependent and linearly-correlated to plasma level of the compound. Minor bleeding was the most commonly reported adverse events. References: Chen X, Liu D, Wu Y, Song H, Liu Y, Jiang J, Hu P. A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30-90 mg in healthy Chinese volunteers. Xenobiotica. 2017 Jul;47(7):592-599. doi: 10.1080/00498254.2016.1207825. Epub 2016 Aug 25. PubMed PMID: 27560456.

纯度：≥98%

CAS：834919-19-6